Xbrane Bioscience has signed an agreement with an Indian company in helping them to develop a bacterial system for protein production.
Under the agreement, Xbrane will develop a system for the manufacturing of a biosimilar protein pharmaceutical.
In an interview with Kemivärlden Biotech Xbrane Biosciences’ CEO Siavash Bashiri says that they cannot reveal which pharmaceutical company they have signed the agreement with. But according to Bashiri it is a global Indian company that is currently entering the biosimilar market and that wants their help in streamlining the production. Bashiri also said that this is Xbrane’s biggest deal thus far.
The plan is to have the drug ready to reach a clinic in April 2015. In exchange for their services Xbrane will get milestone payments before and after the launch as well as royalties from the sale. The company expects to get between SEK 10-15 million through the collaboration during the next 4-5 years, said Bashiri.
